CL2017000402A1 - Anticuerpos anti-vasa y métodos de producción y uso de los mismos - Google Patents

Anticuerpos anti-vasa y métodos de producción y uso de los mismos

Info

Publication number
CL2017000402A1
CL2017000402A1 CL2017000402A CL2017000402A CL2017000402A1 CL 2017000402 A1 CL2017000402 A1 CL 2017000402A1 CL 2017000402 A CL2017000402 A CL 2017000402A CL 2017000402 A CL2017000402 A CL 2017000402A CL 2017000402 A1 CL2017000402 A1 CL 2017000402A1
Authority
CL
Chile
Prior art keywords
mabs
methods
vase
cdrs
production
Prior art date
Application number
CL2017000402A
Other languages
English (en)
Inventor
David T Weaver
Bo Zhang
Original Assignee
Ovascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovascience Inc filed Critical Ovascience Inc
Publication of CL2017000402A1 publication Critical patent/CL2017000402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

<p>SE DIVULGAN ANTICUERPOS ANTI-VASA (MABS), PARTICULARMENTE MABS HUMANIZADOS QUE SE UNEN ESPECÍFICAMENTE A VASA CON ALTA AFINIDAD. SE PROPORCIONAN LAS SECUENCIAS DE AMINOÁCIDOS DE LOS CDRS DE CADENAS LIGERAS Y CADENAS PESADAS, ASÍ COMO SECUENCIAS DE CONSENSO PARA ESTOS CDRS, DE ESTOS MABS ANTI-VASA. LA DIVULGACIÓN TAMBIÉN PROPORCIONA MOLÉCULAS DE ÁCIDO NUCLÉICO QUE CODIFICAN LOS MABS ANTI VASA, VECTORES DE EXPRESIÓN, CÉLULAS HUÉSPED, MÉTODOS PARA HACER LOS MABS ANTI-VASA Y MÉTODOS PARA EXPRESAR LOS MABS ANTI-VASA. FINALMENTE, SE DIVULGAN MÉTODOS PARA USAR LOS MABS ANTI-VASA PARA AISLAR Y/O PURIFICAR LAS CÉLULAS QUE EXPRESAN VASA.</p>
CL2017000402A 2014-09-16 2017-02-17 Anticuerpos anti-vasa y métodos de producción y uso de los mismos CL2017000402A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08

Publications (1)

Publication Number Publication Date
CL2017000402A1 true CL2017000402A1 (es) 2017-11-03

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000402A CL2017000402A1 (es) 2014-09-16 2017-02-17 Anticuerpos anti-vasa y métodos de producción y uso de los mismos

Country Status (26)

Country Link
US (4) US9403913B2 (es)
EP (1) EP3194448A4 (es)
JP (2) JP2017532953A (es)
KR (1) KR20170056521A (es)
CN (1) CN106573985A (es)
AP (1) AP2017009758A0 (es)
AU (1) AU2015317813B2 (es)
BR (1) BR112017003263A2 (es)
CA (1) CA2959179A1 (es)
CL (1) CL2017000402A1 (es)
CO (1) CO2017001724A2 (es)
CR (1) CR20170067A (es)
DO (1) DOP2017000050A (es)
EA (1) EA201790236A1 (es)
EC (1) ECSP17011262A (es)
GT (1) GT201700036A (es)
IL (1) IL250451A0 (es)
MX (1) MX358243B (es)
NI (1) NI201700022A (es)
PE (1) PE20170667A1 (es)
PH (1) PH12017500309A1 (es)
SG (1) SG11201701016WA (es)
SV (1) SV2017005393A (es)
TN (1) TN2017000066A1 (es)
TW (1) TW201619194A (es)
WO (1) WO2016044436A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2473565C2 (ru) 2006-04-07 2013-01-27 Аерпио Терапетикс, Инк. АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ТИРОЗИН ФОСФАТАЗУ БЕТА ЧЕЛОВЕКА (HPTPβ), И ИХ ИСПОЛЬЗОВАНИЕ
JP2014530244A (ja) 2011-10-13 2014-11-17 エアピオ セラピューティックス， インコーポレイテッド 血管漏出症候群および癌を治療する方法
MX358243B (es) * 2014-09-16 2018-08-10 Ovascience Inc Anticuerpos anti-vasa y metodos de produccion y uso de los mismos.
EP3487518A4 (en) 2016-07-20 2020-08-12 Aerpio Therapeutics LLC HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS)
JP2022502367A (ja) 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
US20220380442A1 (en) * 2019-11-11 2022-12-01 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefore

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6094696A (en) * 1995-06-05 1996-12-24 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
EP1233978A4 (en) 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
US20060010509A1 (en) 2004-05-17 2006-01-12 Joshua Johnson Methods and compositions for producing germ cells from bone marrow derived germline stem cells
UA94019C2 (ru) * 2004-07-09 2011-04-11 Чугаи Сейяку Кабусики Кайся Антитело, которое специфически связывается с глипиканом 3 (gpc3)
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2009297872A1 (en) 2008-09-25 2010-04-01 National University Corporation Tokyo University Of Marine Science And Technology Anti-tuna Vasa antibody
CA2748990A1 (en) * 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
JP5769316B2 (ja) * 2009-08-06 2015-08-26 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
EP2697365A4 (en) 2011-04-14 2014-07-23 Gen Hospital Corp COMPOSITIONS AND METHODS FOR AUTOLOGOUS ENERGY TRANSMISSION IN MITOCHONDRIAL GLAND LINES
JP6284475B2 (ja) * 2011-06-29 2018-02-28 ザ ジェネラル ホスピタル コーポレイション 雌性生殖細胞における生体エネルギー状態を増強するための組成物及び方法
AU2013370009B2 (en) * 2012-12-31 2016-11-17 Academia Sinica Anti-granulysin antibodies and methods of use thereof
MX358243B (es) * 2014-09-16 2018-08-10 Ovascience Inc Anticuerpos anti-vasa y metodos de produccion y uso de los mismos.
AU2016206945A1 (en) * 2015-01-13 2017-08-10 President And Fellows Of Harvard College Purification of germ stem cells by targeting MRP9

Also Published As

Publication number Publication date
US20170107299A1 (en) 2017-04-20
PE20170667A1 (es) 2017-06-06
CR20170067A (es) 2017-05-10
WO2016044436A2 (en) 2016-03-24
AU2015317813B2 (en) 2018-04-05
US9567404B2 (en) 2017-02-14
JP2017532953A (ja) 2017-11-09
US20180155445A1 (en) 2018-06-07
KR20170056521A (ko) 2017-05-23
EP3194448A2 (en) 2017-07-26
IL250451A0 (en) 2017-03-30
JP2018148915A (ja) 2018-09-27
TN2017000066A1 (en) 2018-07-04
BR112017003263A2 (pt) 2017-11-28
EA201790236A1 (ru) 2017-11-30
SV2017005393A (es) 2017-06-07
CO2017001724A2 (es) 2017-07-19
US20160311929A1 (en) 2016-10-27
TW201619194A (zh) 2016-06-01
CA2959179A1 (en) 2016-03-24
PH12017500309A1 (en) 2017-07-10
WO2016044436A3 (en) 2016-06-09
ECSP17011262A (es) 2017-05-31
US9403913B2 (en) 2016-08-02
SG11201701016WA (en) 2017-03-30
NI201700022A (es) 2017-05-04
CN106573985A (zh) 2017-04-19
DOP2017000050A (es) 2018-04-15
EP3194448A4 (en) 2018-03-14
AU2015317813A1 (en) 2017-03-02
MX2017002390A (es) 2017-07-28
GT201700036A (es) 2018-12-19
AP2017009758A0 (en) 2017-02-28
US20160075797A1 (en) 2016-03-17
MX358243B (es) 2018-08-10

Similar Documents

Publication Publication Date Title
CL2017000402A1 (es) Anticuerpos anti-vasa y métodos de producción y uso de los mismos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CL2017002820A1 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
CO2017013398A2 (es) Anticuerpos anti-ctla-4
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
GB2549632A (en) Fusion protein comprising three binding domains to 5TA and CD3
MX2016016886A (es) Anticuerpos anti-axl.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
AR088941A1 (es) Anticuerpos anti-fgfr2 y sus usos
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
EP3292198A4 (en) Reversion of primed pluripotent stem cells to naive pluripotent stem cells
BR112015000982B8 (pt) Método para a obtenção de uma molécula de ácido nucleico sintético
UY37377A (es) Anticuerpos multiespecíficos que facilitan el emparejamiento selectivo de cadenas ligeras
CO2017006157A2 (es) Método de manufactura de proteína
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra
EA201692057A1 (ru) Композиции и способы повышения производства
AR121863A2 (es) Proteínas biespecíficas de unión a cd33 y cd3
AR101891A1 (es) Anticuerpos anti-vasa, y métodos de producción y uso de los mismos
CR20150249A (es) Móleculas de unión al dominio de fibronectina de tipo iii de egfr y c-met